[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337248-105":59,"doc-detail-337248-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","role-of-silent-mutations-in-kras-mutant-tumors","Role of silent mutations in KRAS-mutant tumors","","Silent mutations within the RAS gene have attracted growing interest for their potential contributions to tumorigenesis and therapeutic strategies. Kirsten-RAS (KRAS) mutations, largely oncogenic, are key drivers across many cancers. In contrast to active KRAS mutations, the functional impact of silent variants remains insufficiently explored. This review consolidates current evidence showing that silent mutations, although not changing protein sequences, can influence RNA stability and translational efficiency, affecting cancer development and highlighting possible diagnostic and treatment implications.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/role-of-silent-mutations-in-kras-mutant-tumors/337248/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/role-of-silent-mutations-in-kras-mutant-tumors/337248.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are silent mutations in KRAS being studied more recently?","Question",{"text":112,"@type":113},"Silent mutations in KRAS are increasingly recognized for their potential roles in tumorigenesis and therapeutic strategies, even though they do not alter protein sequences directly.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How can silent KRAS mutations affect cancer biology without changing the protein sequence?",{"text":117,"@type":113},"They can affect RNA stability and translational efficiency, which can in turn influence tumor development and KRAS-driven signaling.",{"name":119,"@type":110,"acceptedAnswer":120},"What regulates KRAS protein activity between inactive and active states?",{"text":121,"@type":113},"KRAS activity is determined by its nucleotide-bound state: GDP-bound KRAS is inactive, while GTP-bound KRAS is active, enabling interaction with downstream pathways.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337248,1790167933,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Role of silent mutations in KRAS-mutant tumors  \nJun Lu1,2,3,4, Chao Zhou1, Feng Pan1, Hongyu Liu1, Haohua Jiang1, Hua Zhong1,3, Baohui Han1,2,3  \n1Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; 2Shanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China;  \n3Translational Medical Research Platform for Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; 4Department of Bio-bank, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.  \nAbstract  \nSilent mutations within the RAS gene have garnered increasing attention for their potential roles in tumorigenesis and therapeutic strategies. Kirsten-RAS (KRAS) mutations, predominantly oncogenic, are pivotal drivers in various cancers. While extensive research has elucidated the molecular mechanisms and biological consequences of active KRAS mutations, the functional significance of silent mutations remains relatively understudied. This review synthesizes current knowledge on KRAS silent mutations, highlighting their impact on cancer development. Silent mutations, which do not alter protein sequences but can affect RNA stability and translational efficiency, pose intriguing questions regarding their contribution to tumor biology. Understanding these mutations is crucial for comprehensively unraveling KRAS-driven oncogenesis and exploring novel therapeutic avenues. Moreover, investigations into the clinical implications of silent mutations in KRAS-mutant tumors suggest potential diagnostic and therapeutic strategies. Despite being in early stages, research on KRAS silent mutations holds promise for uncovering novel insights that could inform personalized cancer treatments. In conclusion, this review underscores the evolving landscape of KRAS silent mutations, advocating for further exploration to bridge fundamental biology with clinical applications in oncology. Keywords: KRAS mutations; Silent mutation; Tumor; Biological characteristics  \nIntroduction  \nRAS is recognized as the first tumor oncogene in humans, isolated from soft-tissue tumors. [1] As one of the most common driver genes in cancers, the RAS oncogene consists of Harvey-RAS (HRAS ), Neuroblastoma-RAS (NRAS ), and Kirsten-RAS (KRAS ) . [2] KRAS mutation accounts for approximately 85% of RAS variations inhuman cancers. The KRAS encoding gene is situated on the short arm of chromosome 12 (12p11.1-12.1), comprising six exons. And, the encoded protein of KRAS is a guanosine-binding protein with guanosine triphosphatase activity, GTPase KRas (KRAS), consisting of either 188 or 189 amino acids and exhibiting a molecular weight of 21.6 kDa. [3]  \nUsually, the activity of KRAS protein is inhibited strictly in normal cells. Nevertheless, the “inactive” state of the protein is unleashed upon specific mutations in KRAS encoding region, such as G12C, G12D, G12S, G12V, Q61H, etc. Subsequently, the activation of downstream pathways in KRAS ultimately leads to tumorigenesis. [4] The heterogeneous and bioactivities of KRAS mutations have been identified extensively. [5,6] Our attention is often  \n\n| Access this article online |  |\n| --- | --- |\n| Quick Response Code: | Website:\u003Cbr>[www.cmj.org](www.cmj.org) |\n|  | DOI:\u003Cbr>10.1097/CM9.0000000000003405 |\n\ndirected toward non-silent mutations rather than silent mutations, due to the latter historically regarded as predominantly neutral. As investigation into KRAS function deepens, silent mutations are increasingly recognized for their significant roles in tumorigenesis. [7]  \nIn this review, we provide a comprehensive overview of the biological functions associated with KRAS mutations, with particular emphasis on elucidating the role of silent mutations in KRAS-mutant tumors.  \nKRAS Mutation-Mediated Tu","cbCaigoJxzqNgY3s","https://ap.wps.com/l/cbCaigoJxzqNgY3s","pdf",11307533,11,"English","# Introduction\n# KRAS Mutation-Mediated Tumorigenesis\n## Regulation of KRAS protein activity\n## GDP- and GTP-bound KRAS states\n## Upstream regulators (e.g., GAP/NF1)\n# Conclusion","[{\"question\":\"Why are silent mutations in KRAS being studied more recently?\",\"answer\":\"Silent mutations in KRAS are increasingly recognized for their potential roles in tumorigenesis and therapeutic strategies, even though they do not alter protein sequences directly.\"},{\"question\":\"How can silent KRAS mutations affect cancer biology without changing the protein sequence?\",\"answer\":\"They can affect RNA stability and translational efficiency, which can in turn influence tumor development and KRAS-driven signaling.\"},{\"question\":\"What regulates KRAS protein activity between inactive and active states?\",\"answer\":\"KRAS activity is determined by its nucleotide-bound state: GDP-bound KRAS is inactive, while GTP-bound KRAS is active, enabling interaction with downstream pathways.\"}]","Role of silent mutations in KRAS-mutant tumors | PDF",1790018333,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cdf3d0c0ea227577feccf9b1b24a2729.webp",983,1324,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2cb83b05701f231ed03fed983760bbf1.webp",982,1323,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee636119ff5de38c442054fd3bdd2ae9.webp",981,1321,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7bde1ca4610d8fc9c8fc32f409a53c53.webp",980,1320]